For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved ...

On June 12, 2024, the FDA granted traditional approval to selpercatinib for the treatment of for adult and pediatric patients ...

Amivantamab plus lazertinib improved PFS over osimertinib as first-line treatment for patients with EGFR-mutant, advanced NSCLC.

Matthew Triplette, Fred Hutchinson Cancer Center and University of Washington, Seattle, USA, delivered an insightful ...

If you or a loved one are considering volunteering for an ovarian cancer clinical trial, here’s what to know about the ...

Michigan marijuana regulators know some vaping products contain a potentially harmful ingredient, but they don’t plan to test ...

The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame ...

Inequality in cancer care appears to be associated with patients’ socioeconomic status. The lower the income level the less ...

Cryptococcal meningitis is more common in Africa. People with weakened immune systems, especially from HIV or AIDS, are at ...

By Katabella Roberts Contributing Writer The Centers for Disease Control and Prevention has changed its recommendations ...

Researchers reported a natural infection of a highly pathogenic avian influenza A(H5N1) virus in a free-ranging juvenile ...

Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E ...